F2RL3 methylation, lung cancer incidence and mortality

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1739-1748

  Zhang, Yan ^a   Schöttker, Ben ^a   Ordóñez Mena, José ^a,b   Holleczek, Bernd ^c   Yang, Rongxi ^a,b   Burwinkel, Barbara ^a,b   Butterbach, Katja ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SAARLAND CANCER REGISTRY   (Germany)

Author keywords

F2RL3 methylation; lung cancer; PAR 4; prospective study; smoking

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR 4; PROTEASE-ACTIVATED RECEPTOR 4; THROMBIN RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; EARLY CANCER DIAGNOSIS; F2RL3 GENE; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SMOKING AND SMOKING RELATED PHENOMENA; SMOKING EXPOSURE; SMOKING HABIT; SMOKING PACK YEAR; SMOKING STATUS; STATISTICS; GENETICS; GERMANY; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY;

AGED; COHORT STUDIES; DNA METHYLATION; FEMALE; GERMANY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, THROMBIN; SMOKING;

EID: 84943420803     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29537     Document Type: Article

References (53)

1. Ferlay J, Soerjomataram I, Ervik M, et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. http://globocan.iarc.fr
2. Khuder SA,. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001; 31: 139-48.
3. Mathers C, Stevens G, Mascarenhas M., Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks ed. Geneva: World Health Organization, 2009. http://www.who.int/healthinfo/global-burden-disease/GlobalHealthRisks-report-full.pdf
4. Centers for Disease Control and Prevention (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon Generaled. Atlanta (GA), 2010. http://www.ncbi.nlm.nih.gov/pubmed/21452462
5. Gibbons DL, Byers LA, Kurie JM,. Smoking, p53 mutation, and lung cancer. Mol Cancer Res 2014; 12: 3-13.
6. Belinsky SA,. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4: 707-17.
7. Selamat SA, Chung BS, Girard L, et al., Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res 2012; 22: 1197-211.
8. Baylin SB, Jones PA,. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-34.
9. Scherf DB, Sarkisyan N, Jacobsson H, et al., Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of chrnb4. Oncogene 2013; 32: 3329-38.
10. Belinsky SA, Nikula KJ, Palmisano WA, et al., Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95: 11891-6.
11. Palmisano WA, Divine KK, Saccomanno G, et al., Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-8.
12. Brock MV, Hooker CM, Ota-Machida E, et al., DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358: 1118-28.
13. Tsou JA, Hagen JA, Carpenter CL, et al., DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002; 21: 5450-61.
14. Balgkouranidou I, Liloglou T, Lianidou ES,. Lung cancer epigenetics: emerging biomarkers. Biomark Med 2013; 7: 49-58.
15. Breitling LP, Yang R, Korn B, et al., Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet 2011; 88: 450-7.
16. Shenker NS, Polidoro S, van Veldhoven K, et al., Epigenome-wide association study in the european prospective investigation into cancer and nutrition (EPIC-turin) identifies novel genetic loci associated with smoking. Hum Mol Genet 2013; 22: 843-51.
17. Zeilinger S, Kuhnel B, Klopp N, et al., Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One 2013; 8: e63812
18. Wan ES, Qiu W, Baccarelli A, et al., Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet 2012; 21: 3073-82.
19. Sun YV, Smith AK, Conneely KN, et al., Epigenomic association analysis identifies smoking-related DNA methylation sites in African Americans. Hum Genet 2013; 132: 1027-37.
20. Elliott HR, Tillin T, McArdle WL, et al., Differences in smoking associated DNA methylation patterns in South Asians and Europeans. Clin Epigenetics 2014; 6: 4
21. Zhang Y, Yang R, Burwinkel B, et al., F2rl3 methylation as a biomarker of current and lifetime smoking exposures. Environ Health Perspect 2014; 122: 131-7.
22. Zhang Y, Yang R, Burwinkel B, et al., F2rl3 methylation in blood DNA is a strong predictor of mortality. Int J Epidemiol 2014; 43: 1215-25.
23. Schoettker B, Muller H, Rothenbacher D, et al., Fasting plasma glucose and HbA(1c) in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus. Diabetologia 2013; 56: 92-100.
24. Miller SA, Dykes DD, Polesky HF,. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
25. Desquilbet L, Mariotti F,. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 2010; 29: 1037-57.
26. Harrell FE, Jr., Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
27. Efron B, Tibshirani R,. Improvements on Cross-validation: the.632+ bootstrap method. J Am Stat Assoc 1997; 92: 548-60.
28. Miao Y, Cenzer I, Kirby K, et al., Estimating Harrell's optimism on predictive indices using bootstrap samples. Proc SAS Global 2013; 2013: 504-2013. http://support.sas.com/resources/papers/proceedings13/504-2013.pdf.
29. Xu WF, Andersen H, Whitmore TE, et al., Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998; 95: 6642-6.
30. Elste AP, Petersen I,. Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer. J Mol Histol 2010; 41: 89-99.
31. Black PC, Mize GJ, Karlin P, et al., Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate 2007; 67: 743-56.
32. Gratio V, Walker F, Lehy T, et al., Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves src and ErbB-2 kinase. Int J Cancer 2009; 124: 1517-25.
33. Kaufmann R, Rahn S, Pollrich K, et al., Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol 2007; 211: 699-707.
34. Chen HT, Tsou HK, Tsai CH, et al., Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway. J Cell Physiol 2010; 223: 737-45.
35. Ghio P, Cappia S, Selvaggi G, et al., Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 395-400.
36. Walter J, Handel LL, Brodhun M, et al., Expression of coagulation factors and their receptors in tumor tissue and coagulation factor upregulation in peripheral blood of patients with cerebral carcinoma metastases. J Cancer Res Clin Oncol 2012; 138: 141-51.
37. Jiang P, Yu GY, Zhang Y, et al., Down-regulation of protease-activated receptor 4 in lung adenocarcinoma is associated with a more aggressive phenotype. Asian Pac J Cancer Prev 2013; 14: 3793-8.
38. Ferrigno D, Buccheri G, Ricca I,. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 2001; 17: 667-73.
39. Voulgaris E, Pentheroudakis G, Vassou A, et al., Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature. Lung Cancer 2009; 64: 247-9.
40. McKay JD, Hung RJ, Gaborieau V, et al., Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008; 40: 1404-6.
41. Wang Y, Broderick P, Webb E, et al., Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008; 40: 1407-9.
42. Radzikowska E, Roszkowski K, Glaz P,. Lung cancer in patients under 50 years old. Lung Cancer 2001; 33: 203-11.
43. Yang P, Bamlet WR, Ebbert JO, et al., Glutathione pathway genes and lung cancer risk in young and old populations. Carcinogenesis 2004; 25: 1935-44.
44. Manser R, Lethaby A, Irving LB, et al., Screening for lung cancer. Cochrane Database Syst Rev 2013; 6: cd001991
45. National Lung Screening Trial Research T, Aberle DR, Adams AM, et al., Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;3 65: 395-409.
46. Croswell JM, Baker SG, Marcus PM, et al., Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med 2010; 152: 505-12. W176-80.
47. Field JK, Smith RA, Aberle DR, et al., International association for the study of lung cancer computed tomography screening workshop 2011 report. J Thorac Oncol 2012; 7: 10-9.
48. Nikolaidis G, Raji OY, Markopoulou S, et al., DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res 2012; 72: 5692-701.
49. Kneip C, Schmidt B, Seegebarth A, et al., Shox2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 2011; 6: 1632-8.
50. Dietrich D, Kneip C, Raji O, et al., Performance evaluation of the DNA methylation biomarker shox2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol 2012; 40: 825-32.
51. Raji OY, Duffy SW, Agbaje OF, et al., Predictive accuracy of the liverpool lung project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med 2012; 157: 242-50.
52. Reinius LE, Acevedo N, Joerink M, et al., Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS One 2012; 7: e41361
53. Tsaprouni LG, Yang TP, Bell J, et al., Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. Epigenetics 2014; 9: 1382-96.